Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease

Journal of Neuroscience

Volumn 22, Issue 5, 2002, Pages 1763-1771

  Wu, Du Chu ^a   Jackson Lewis, Vernice ^a   Vila, Miquel ^a   Tieu, Kim ^a   Teismann, Peter ^a   Vadseth, Caryn ^b   Choi, Dong Kug ^a   Ischiropoulos, Harry ^b   Przedborski, Serge ^a  

^a Columbia University ^*  (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

IL 1 ; INOS; Microglia; Minocycline; MPTP; NADPH oxidase; Neurodegeneration; Parkinson's disease

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3 NITROTYROSINE; INTERLEUKIN 1BETA; MINOCYCLINE; NEUROTOXIN; NITRIC OXIDE SYNTHASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CONTROLLED STUDY; CYTOTOXICITY; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; MALE; MICROGLIA; MOUSE; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; STRIATONIGRAL DEGENERATION; SYNAPTOSOME;

EID: 0036522967     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.22-05-01763.2002     Document Type: Article

References (42)

1. Amin AR, Attur MG, Thakker GD, Patel PD, Vyas PR, Patel RN, Patel IR, Abramson SB (1996) A novel mechanism of action of tetracyclines: Effects on nitric oxide synthases. Proc Natl Acad Sci USA 93:14014-14019.
2. Ara J, Przedborski S, Naini AB, Jackson-Lewis V, Trifiletti RR, Horwitz J, Ischiropoulos H (1998) Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Proc Natl Acad Sci USA 95:7659-7663.
3. Aronson AL (1980) Pharmacotherapeutics of the newer tetracyclines. J Am Vet Med Assoc 176:1061-1068.
4. Banati RB, Gehrmann J, Schubert P, Kreutzberg GW (1993) Cytotoxicity of microglia. Glia 7:111-118.
5. Burke RE, Cadet JL, Kent JL, Karanas AL, Jackson-Lewis V (1990) An assessment of the validity of densitometric measures of striatal tyrosine hydroxylase-positive fibers: Relationship to apomorphine-induced rotations in 6-hydroxydopamine lesioned rats. J Neurosci Methods 35:63-73.
6. Castano A, Herrera AJ, Cano J, Machado A (1998). Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. J Neurochem 70:1584-1592.
7. Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, Bian J, Guo L, Farrell LA, Hersch SM, Hobbs W, Vonsattel JP, Cha JH, Friedlander RM (2000) Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 6:797-801.
8. Dehmer T, Lindenau J, Haid S, Dichgans J, Schulz JB (2000) Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. J Neurochem 74:2213-2216.
9. Fahn S, Przedborski S (2000) Parkinsonism. In: Merritt's Neurology (Rowland LP, ed), pp 679-693. New York: Lippincott Williams & Wilkins.
10. Gehrmann J, Matsumoto Y, Kreutzberg GW (1995) Microglia: Intrinsic immuneffector cell of the brain. Brain Res Rev 20:269-287.
11. Giovanni A, Sieber BA, Heikkila RE, Sonsalla PK (1991) Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice. J Pharmacol Exp Ther 257:691-697.
12. Halliwell B, Gutteridge JM (1991) Free Radicals in Biology and Medicine. Oxford: Clarendon.
13. He Y, Appel S, Le W (2001) Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res 909:187-193.
14. Herrera AJ, Castano A, Venero JL, Cano J, Machado A (2000) The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system. Neurobiol Dis 7:429-447.
15. Hopkins SJ, Rothwell NJ (1995) Cytokines and the nervous system. I. Expression and recognition. Trends Neurosci 18:83-88.
16. Hornykiewicz O, Kish SJ (1987) Biochemical pathophysiology of Parkinson's disease. In: Parkinson's Disease (Yahr M, Bergmann KJ, eds), pp 19-34. New York: Raven.
17. Hunot S, Dugas N, Faucheux B, Hartmann A, Tardieu M, Debre P, Agid Y, Dugas B, Hirsch EC (1999) FceRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-α in glial cells. J Neurosci 19:3440-3447.
18. Jackson-Lewis V, Jakowec M, Burke RE, Przedborski S (1995) Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 4:257-269.
19. Kim WG, Mohney RP, Wilson B, Jeohn GH, Liu B, Hong JS (2000) Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: Role of microglia. J Neurosci 20:6309-6316.
20. Kindt MV, Heikkila RE, Nicklas WJ (1987) Mitochondrial and metabolic toxicity of 1-methyl-4-(2′-methylphenyl)-1,2,3,6-tetrahydropyridine. J Pharmacol Exp Ther 242:858-863.
21. Klevenyi P, Andreassen O, Ferrante RJ, Schleicher JRJ, Friedlander RM, Beal MF (1999) Transgenic mice expressing a dominant negative mutant interleukin-1beta converting enzyme show resistance to MPTP neurotoxicity. NeuroReport 10:635-638.
22. Kostic V, Przedborski S, Flaster E, Sternic N (1991) Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology 41:202-205.
23. Kreutzberg GW (1996) Microglia: A sensor for pathological events in the CNS. Trends Neurosci 19:312-318.
24. Li M, Ona VO, Guegan C, Chen M, Jackson-Lewis V, Andrews LJ, Olszewski AJ, Stieg PE, Lee JP, Przedborski S, Friedlander RM (2000) Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science 288:335-339.
25. Liberatore GT, Jackson-Lewis V, Vukosavic S, Mandir AS, Vila M, McAuliffe WG, Dawson VL, Dawson TM, Przedborski S (1999) Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 5:1403-1409.
26. Pakkenberg B, Moller A, Gundersen HJG, Mouritzen A, Pakkenberg H (1991) The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method. J Neurol Neurosurg Psychiatry 54:30-33.
27. Pennathur S, Jackson-Lewis V, Przedborski S, Heinecke JW (1999) Mass spectrometric quantification of 3-nitrotyrosine, ortho-tyrosine, and o,o′-dityrosine in brain tissue of 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine-treated mice, a model of oxidative stress in Parkinson's disease. J Biol Chem 274:34621-34628.
28. Przedborski S, Jackson-Lewis V (2000) ROS, Parkinson's disease: A view to a kill. In: Free Radicals in Brain Pathophysiology (Poli G, Cadenas E, Packer L, eds), pp 273-290. New York: Dekker.
29. Przedborski S, Kostic V, Jackson-Lewis V, Naini AB, Simonetti S, Fahn S, Carlson E, Epstein CJ, Cadet JL (1992) Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J Neurosci 12:1658-1667.
30. Przedborski S, Jackson-Lewis V, Yokoyama R, Shibata T, Dawson VL, Dawson TM (1996) Role of neuronal nitric oxide in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)-induced dopaminergic neurotoxicity. Proc Natl Acad Sci USA 93:4565-4571.
31. Przedborski S, Jackson-Lewis V, Djaldetti R, Liberatore G, Vila M, Vukosavic S, Almer G (2000) The parkinsonian toxin MPTP: Action and mechanism. Restor Neurol Neurosci 16:135-142.
32. Przedborski S, Chen Q, Vila M, Giasson BI, Djaldatti R, Vukosavic S, Souza JM, Jackson-Lewis V, Lee VM, Ischiropoulos H (2001a) Oxidative post-translational modifications of alpha-synuclein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. J Neurochem 76:637-640.
33. Przedborski S, Jackson-Lewis V, Naini A, Jakowec M, Petzinger G, Miller R, Akram M (2001b) The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): A technical review of its utility and safety. J Neurochem 76:1265-1274.
34. Sanchez Mejia RO, Ona VO, Li M, Friedlander RM (2001) Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction. Neurosurgery 48:1393-1399.
35. Schulz JB, Matthews RT, Muqit MMK, Browne SE, Beal MF (1995) Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. J Neurochem 64:936-939.
36. Tikka TM, Koistinaho JE (2001) Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia. J Immunol 166:7527-7533.
37. Tikka T, Fiebich BL, Goldsteins G, Keinanen R, Koistinaho J (2001a) Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation, proliferation of microglia. J Neurosci 21:2580-2588.
38. Tikka T, Usenius T, Tenhunen M, Keinanen R, Koistinaho J (2001b) Tetracycline derivatives and ceftriaxone, a cephalosporin antibiotic, protect neurons against apoptosis induced by ionizing radiation. J Neurochem 78:1409-1414.
39. Vila M, Jackson-Lewis V, Vukosavic S, Djaldetti R, Liberatore G, Offen D, Korsmeyer SJ, Przedborski S. (2001a) Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Proc Natl Acad Sci USA 98:2837-2842.
40. Vila M, Jackson Lewis V, Guégan C, Wu DC, Teismann P, Choi D-K, Tieu K, Przedborski S (2001b) The role of glial cells in Parkinson's disease. Curr Opin Neurol 14:483-489.
41. Yrjanheikki J, Keinanen R, Pellikka M, Hokfelt T, Koistinaho J (1998) Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci USA 95:15769-15774.
42. Yrjanheikki J, Tikka T, Keinanen R, Goldsteins G, Chan PH, Koistinaho J (1999) A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci USA 96:13496-13500.